Cadrenal Therapeutics, Inc. financial data

Symbol
CVKD on Nasdaq
Industry
Pharmaceutical Preparations
Location
822 A1 A North, Suite 300, Ponte Vedra, FL
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 815 %
Debt-to-equity 14 %
Return On Equity -93.7 % +99%
Return On Assets -82.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16M shares +22.9%
Common Stock, Shares, Outstanding 16M shares +36.6%
Entity Public Float 6.4M USD -51.8%
Common Stock, Value, Issued 16K USD +36.6%
Weighted Average Number of Shares Outstanding, Basic 16M shares +36.6%
Weighted Average Number of Shares Outstanding, Diluted 16M shares +36.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.49M USD -61.9%
General and Administrative Expense 4.14M USD +14.2%
Operating Income (Loss) -6.63M USD +8.89%
Nonoperating Income (Expense) 392K USD +218%
Net Income (Loss) Attributable to Parent -6.24M USD +48.9%
Earnings Per Share, Basic -0.3 USD/shares +77.4%
Earnings Per Share, Diluted -0.3 USD/shares +79.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.04M USD
Assets, Current 5.44M USD +54.7%
Property, Plant and Equipment, Net 1.22K USD -64.9%
Operating Lease, Right-of-Use Asset 8.66K USD -73.5%
Other Assets, Noncurrent 3.79K USD 0%
Assets 5.46M USD +53.3%
Accounts Payable, Current 760K USD +872%
Employee-related Liabilities, Current 437K USD
Accrued Liabilities, Current 697K USD +156%
Liabilities, Current 1.46M USD +291%
Operating Lease, Liability, Noncurrent 2.23K USD
Liabilities 1.46M USD +282%
Retained Earnings (Accumulated Deficit) -19.1M USD -48.4%
Stockholders' Equity Attributable to Parent 3.99M USD +25.7%
Liabilities and Equity 5.46M USD +53.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.84M USD -30%
Net Cash Provided by (Used in) Financing Activities 5.41M USD +969%
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 16M shares +36.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.04M USD +56%
Deferred Tax Assets, Valuation Allowance 2.18M USD +355%
Deferred Tax Assets, Gross 2.19M USD +311%
Operating Lease, Liability 8.8K USD -73.2%
Depreciation 2.26K USD -21.3%
Lessee, Operating Lease, Liability, to be Paid 8.93K USD -74.8%
Operating Lease, Liability, Current 8.8K USD -63.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 22.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 22.3K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 132 USD -94.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 22.3K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.1M USD +269%
Preferred Stock, Shares Authorized 7.5M shares
Additional Paid in Capital 22.7M USD
Preferred Stock, Shares Outstanding 7.5M shares
Share-based Payment Arrangement, Expense 193K USD +15.1%
Interest Expense 41.6K USD +69.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares